172 related articles for article (PubMed ID: 27167326)
1. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.
Zhang J; Zou L; Tang P; Pan D; He Z; Yao D
Eur J Med Chem; 2020 May; 194():112220. PubMed ID: 32222676
[TBL] [Abstract][Full Text] [Related]
4. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
Park JK; Kim S; Han YJ; Kim SH; Kang NS; Lee H; Park S
Bioorg Med Chem Lett; 2016 Jun; 26(11):2580-3. PubMed ID: 27117431
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
Lee W; Crawford JJ; Aliagas I; Murray LJ; Tay S; Wang W; Heise CE; Hoeflich KP; La H; Mathieu S; Mintzer R; Ramaswamy S; Rouge L; Rudolph J
Bioorg Med Chem Lett; 2016 Aug; 26(15):3518-24. PubMed ID: 27346791
[TBL] [Abstract][Full Text] [Related]
6. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
7. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Targeting PAK Signaling.
Senapedis W; Crochiere M; Baloglu E; Landesman Y
Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
[TBL] [Abstract][Full Text] [Related]
9. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
10. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors.
Xu Y; Foulks JM; Clifford A; Brenning B; Lai S; Luo B; Parnell KM; Merx S; McCullar MV; Kanner SB; Ho KK
Bioorg Med Chem Lett; 2013 Jul; 23(14):4072-5. PubMed ID: 23756368
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
[TBL] [Abstract][Full Text] [Related]
13. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
Han D; Wang H; Cui W; Zhang B; Chen BZ
Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
[No Abstract] [Full Text] [Related]
14. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
15. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
Prudnikova TY; Chernoff J
Small GTPases; 2017 Oct; 8(4):193-198. PubMed ID: 27427770
[TBL] [Abstract][Full Text] [Related]
16. From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
Maruta H; Ahn MR
Eur J Med Chem; 2017 Dec; 142():229-243. PubMed ID: 28814374
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
Blake JF; Gaudino JJ; De Meese J; Mohr P; Chicarelli M; Tian H; Garrey R; Thomas A; Siedem CS; Welch MB; Kolakowski G; Kaus R; Burkard M; Martinson M; Chen H; Dean B; Dudley DA; Gould SE; Pacheco P; Shahidi-Latham S; Wang W; West K; Yin J; Moffat J; Schwarz JB
Bioorg Med Chem Lett; 2014 Jun; 24(12):2635-9. PubMed ID: 24813737
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase D1 (PKD1) phosphorylation on Ser
Chang JK; Ni Y; Han L; Sinnett-Smith J; Jacamo R; Rey O; Young SH; Rozengurt E
J Biol Chem; 2017 Jun; 292(23):9523-9539. PubMed ID: 28408623
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.
Le Corre L; Girard AL; Aubertin J; Radvanyi F; Benoist-Lasselin C; Jonquoy A; Mugniery E; Legeai-Mallet L; Busca P; Le Merrer Y
Org Biomol Chem; 2010 May; 8(9):2164-73. PubMed ID: 20401393
[TBL] [Abstract][Full Text] [Related]
20. Role of p21-activated kinases in cardiovascular development and function.
Kelly ML; Astsaturov A; Chernoff J
Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
